Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

This is a real-world observational study looking at how well the drugs sunitinib or sorafenib work in Chinese patients with advanced or metastatic papillary renal cell carcinoma (a specific type of kidney cancer) when used as the first treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with unresectable locally advanced or metastatic papillary renal cell carcinoma (PRCC) - You received sunitinib or sorafenib as your first-line treatment - You have a tumor assessment or clinical visit on record within 6 months of starting treatment **You may NOT be eligible if...** - You have papillary urothelial carcinoma (a different type of kidney cancer) - You had a separate cancer diagnosis in the past 5 years - You received another systemic cancer treatment for PRCC before sunitinib or sorafenib (exceptions apply) Talk to your doctor to see if this trial is right for you.